PubMed Health⌕ Search

PubMed · 15317316

Urticaria: reassessed.

Abstract

Urticaria is a common symptom--it is not a single disease. Patients present knowing what caused their "hives" or not knowing the cause of their hives. The latter patients present to the physician expecting to find a cause--but it is extremely rare that a single cause is discovered; however, a search for identifiable "triggers" should be sought in the history. Routine laboratory investigations are consistently disappointing (unless appropriate testing is suggested by the history). The term idiopathic can be added only when a single putative cause is not discovered. Fortunately, all urticarias eventually resolve (spontaneously). All treatment is palliative. Antihistamines remain the first-line of therapy, the more H1-receptors blocked, the better the results (the majority of patients with urticaria are "undertreated"). Rarely are steroids warranted for management. A review of the evaluation and management of patients with persistent urticaria without an identifiable cause is presented.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Vincent S Beltrani. Urticaria: reassessed.. https://pubmed.ncbi.nlm.nih.gov/15317316/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Meta-analysis: the efficacy of intravenous H2-receptor antagonists in bleeding peptic ulcer.

BACKGROUND: Although a previous meta-analysis found that intravenous H2-receptor antagonists were only weakly beneficial in bleeding gastric ulcer and of no benefit in bleeding duodenal ulcer, patients with ulcer bleeding continue to receive such treatment. AIM: To re-evaluate the efficacy of intravenous H2-receptor antagonists in ulcer re-bleeding, surgery and mortality by updating the previous meta-analysis. METHODS: After two independent literature searches, randomized, placebo-controlled trials of intravenous H2-receptor antagonists in bleeding ulcer published between 1984 and 2000 were added to those from the initial meta-analysis. Pooled rates of re-bleeding, surgery and death were re-calculated, together with the relative risk reduction, absolute risk reduction, number needed to treat and Mantel-Haenszel odds ratio. RESULTS: Intravenous H2-receptor antagonists did not significantly reduce re-bleeding, surgery or death in bleeding duodenal ulcer. There were small but significant reductions in re-bleeding, surgery and death in bleeding gastric ulcer; the absolute risk reductions were 7.2%, 6.7% and 3.2%, respectively. CONCLUSIONS: Intravenous H2-receptor antagonists are of no value in bleeding duodenal ulcer, although they may be mildly beneficial in bleeding gastric ulcer. Because proton pump inhibitors have a greater inhibitory effect on gastric acid secretion than H2-receptor antagonists, they may be more effective in ulcer bleeding and should be further evaluated for that indication.

Histamine H2 Antagonists↗